| abstract |
Disclosed are an abnormal proliferation inhibiting compound of neovascularization represented by the following formula (I), its uses and intermediates. The compound has a beneficial effect on the abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. Such compounds can be used for the treatment of diseases caused by neovascularization abnormalities and protein kinases such as VEGFR2, FGFR2 and the like, for example, macular degeneration, inflammation, malignant tumors and the like. |